secwatch.observer — SEC 8-K summary
======================================

Issuer:     Mirum Pharmaceuticals, Inc. (MIRM)
CIK:        0001759425
Form:       8-K
Filed at:   2023-04-17T23:59:59+00:00
Accession:  0001193125-23-103622
Event type: debt
Sentiment:  neutral
Materiality: 0.65
Item codes: 1.01, 1.02, 2.03, 3.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Mirum prices $316.25M 4.00% convertible notes due 2029; repurchases $192.7M revenue interests
--------------------------------------------------------------------------------

- Issued $316.25M principal (incl. full exercise of $41.25M over-allotment) of 4.00% convertible senior notes due May 1, 2029.
- Initial conversion price ~$31.74/share, a 35% premium over $23.51 closing stock price on April 12, 2023.
- Net proceeds ~$305.4M; used ~$192.7M to repurchase revenue interests from Oberland Capital (RIPA) and terminate that agreement.
- Remaining proceeds expected for general corporate purposes, including working capital and potential acquisitions.
- Notes are senior unsecured; callable by Mirum after May 5, 2026 if stock price >130% of conversion price.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1759425/000119312523103622/0001193125-23-103622-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1759425/000119312523103622/d487416d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-23-103622

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer